DE602008006257D1 - Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c - Google Patents

Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c

Info

Publication number
DE602008006257D1
DE602008006257D1 DE602008006257T DE602008006257T DE602008006257D1 DE 602008006257 D1 DE602008006257 D1 DE 602008006257D1 DE 602008006257 T DE602008006257 T DE 602008006257T DE 602008006257 T DE602008006257 T DE 602008006257T DE 602008006257 D1 DE602008006257 D1 DE 602008006257D1
Authority
DE
Germany
Prior art keywords
hepatitis
cyclopropyl
condensed
treatment
indolobenzazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602008006257T
Other languages
English (en)
Inventor
John A Bender
Zhong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE602008006257D1 publication Critical patent/DE602008006257D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602008006257T 2007-11-21 2008-11-17 Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c Active DE602008006257D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98947207P 2007-11-21 2007-11-21
PCT/US2008/083729 WO2009067392A1 (en) 2007-11-21 2008-11-17 Cyclopropyl fused indolobenzazepine derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
DE602008006257D1 true DE602008006257D1 (de) 2011-05-26

Family

ID=40297935

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602008006257T Active DE602008006257D1 (de) 2007-11-21 2008-11-17 Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c

Country Status (8)

Country Link
US (1) US8124601B2 (de)
EP (1) EP2215095B1 (de)
JP (1) JP2011504178A (de)
CN (1) CN101918412B (de)
AT (1) ATE505473T1 (de)
DE (1) DE602008006257D1 (de)
ES (1) ES2362560T3 (de)
WO (1) WO2009067392A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
WO2009120733A1 (en) 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
AU2009228337A1 (en) 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2655362A1 (de) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis-c-inhibitoren und ihre verwendung
JP6306002B2 (ja) * 2012-07-18 2018-04-04 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ （４ｂＳ，５ａＲ）−１２−シクロヘキシル−Ｎ−（Ｎ，Ｎ−ジメチルスルファモイル）−３−メトキシ−５ａ−（（１Ｒ，５Ｓ）−３−メチル−３，８−ジアザビシクロ［３．２．１］オクタン−８−カルボニル）−４ｂ，５，５ａ，６−テトラヒドロベンゾ［３，４］シクロプロパ［５，６］アゼピノ［１，２−Ａ］インドール−９−カルボキサミドを製造するための新規な方法および中間体
US9616905B2 (en) 2015-06-02 2017-04-11 Westinghouse Air Brake Technologies Corporation Train navigation system and method

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
WO1998047948A1 (en) * 1997-04-18 1998-10-29 California Institute Of Technology Multifunctional polymeric tissue coatings
US6696073B2 (en) * 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
US6855160B1 (en) * 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
US20040009228A1 (en) * 1999-11-30 2004-01-15 Pertti Tormala Bioabsorbable drug delivery system for local treatment and prevention of infections
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040115236A1 (en) * 2000-10-06 2004-06-17 Chan Tai Wah Devices and methods for management of inflammation
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
ATE375145T1 (de) * 2000-12-21 2007-10-15 Alrise Biosystems Gmbh Induziertes phasenübergangs verfahren zur herstellung von hydrophile wirkstoffe enthaltende mikropartikeln
DE10114247A1 (de) * 2001-03-22 2002-10-10 Heraeus Kulzer Gmbh & Co Kg Antibiotikum-/Antibiotika-Polymer-Kombination
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6648849B2 (en) * 2001-06-27 2003-11-18 Ethicon, Inc. Medicinal implant and device and method for loading and delivering implants containing drugs and cells
EP1411861B1 (de) * 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biologisch abbaubare injizierbare implantate und verwandte herstellungs- und verwendungsmethoden
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
GB2404865B (en) * 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
IN2014DN10834A (de) * 2001-09-17 2015-09-04 Psivida Inc
US6827737B2 (en) * 2001-09-25 2004-12-07 Scimed Life Systems, Inc. EPTFE covering for endovascular prostheses and method of manufacture
US6926903B2 (en) * 2001-12-04 2005-08-09 Inion Ltd. Resorbable polymer composition, implant and method of making implant
AU2002351388A1 (en) * 2001-12-14 2003-06-30 The University Of Wyoming Methods and compositions for controlled release of drugs
NZ534317A (en) * 2002-01-24 2006-06-30 Smart Drug Systems Inc Sustained release pharmaceutical composition carried in or on silicone support material
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
TW200400963A (en) * 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
US7049348B2 (en) * 2002-07-06 2006-05-23 Kensey Nash Corporation Resorbable structure for treating and healing of tissue defects
US20040006146A1 (en) * 2002-07-06 2004-01-08 Evans Douglas G. Resorbable structure for treating and healing of tissue defects
US6916483B2 (en) * 2002-07-22 2005-07-12 Biodynamics, Llc Bioabsorbable plugs containing drugs
DK1545389T3 (da) * 2002-07-31 2020-07-20 Mast Biosurgery Ag Indretning til forebyggelse af adhæsioner mellem et implantat og omgivende væv
CA2495172A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
US7951392B2 (en) * 2002-08-16 2011-05-31 Boston Scientific Scimed, Inc. Microarray drug delivery coatings
US20050070989A1 (en) * 2002-11-13 2005-03-31 Whye-Kei Lye Medical devices having porous layers and methods for making the same
US7758881B2 (en) * 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050079199A1 (en) * 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
US20080051866A1 (en) * 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
US20060083767A1 (en) * 2003-02-27 2006-04-20 Kai Deusch Surgical prosthesis having biodegradable and nonbiodegradable regions
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
EA011169B1 (ru) * 2003-03-14 2009-02-27 Дебио Решерш Фармасётик С.А. Система подкожной доставки, способ ее получения и ее применение для лечения холинергических дефицитных расстройств
ES2359977T3 (es) * 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
US8007823B2 (en) * 2003-04-03 2011-08-30 Corporation De L'ecole Polytechnique De Montreal Microporous articles comprising biodegradable medical polymers, method of preparation thereof and method of use thereof
US20060105018A1 (en) * 2004-11-17 2006-05-18 Epstein Samuel J Therapeutic driving layer for a medical device
EP1633320A2 (de) * 2003-05-02 2006-03-15 SurModics, Inc. Implantierbares system zur kontrollierten freisetzung eines bioaktiven wirkstoffs
JP2007504920A (ja) * 2003-05-16 2007-03-08 ブルー メンブレーンス ゲーエムベーハー 生体適合性コーティングされた医療用インプラント
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
JP2006526424A (ja) * 2003-06-04 2006-11-24 イニオン リミテッド 生分解性インプラントおよびその製造方法
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
US20070116738A1 (en) * 2003-06-26 2007-05-24 Patrice Mauriac Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
FI20045223A (fi) * 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US8870814B2 (en) * 2003-07-31 2014-10-28 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing silicone copolymer for controlled delivery of therapeutic agent
US9114199B2 (en) * 2003-07-31 2015-08-25 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US7914805B2 (en) * 2003-07-31 2011-03-29 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agent
US7357940B2 (en) * 2003-07-31 2008-04-15 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing graft copolymer for controlled delivery of therapeutic agents
US20050037047A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices comprising spray dried microparticles
US8529625B2 (en) * 2003-08-22 2013-09-10 Smith & Nephew, Inc. Tissue repair and replacement
CA2539568C (en) * 2003-09-23 2013-09-10 Orthotherapeutics, Llc Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US20050118229A1 (en) * 2003-10-21 2005-06-02 Imedd, Inc. Implantable drug delivery device for sustained release of therapeutic agent
US7435256B2 (en) * 2003-11-06 2008-10-14 Boston Scientific Scimed, Inc. Method and apparatus for controlled delivery of active substance
JP2007517042A (ja) * 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
DK1719773T3 (da) 2004-02-24 2009-06-29 Japan Tobacco Inc Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
WO2006002399A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
EP1809349B1 (de) * 2004-07-05 2009-10-14 Ziscoat N.V. Biokompatible beschichtung von medizinischen vorrichtungen mit molekularsieben
SI1629844T1 (sl) * 2004-07-13 2007-12-31 Bayer Schering Pharma Oy Sistem podaljšanega oddajanja s kontrolirano začetno dozo
US7713539B2 (en) * 2004-07-19 2010-05-11 Boston Scientific Scimed, Inc. Medical devices containing radiation resistant block copolymer
US7771740B2 (en) * 2004-07-19 2010-08-10 Boston Scientific Scimed, Inc. Medical devices containing copolymers with graft copolymer endblocks for drug delivery
CA2575988C (en) * 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
JP4906723B2 (ja) * 2004-08-13 2012-03-28 マスト バイオサージェリー アクチェンゲゼルシャフト 生分解性および非生分解性領域を有する外科用補綴物
US20060039946A1 (en) * 2004-08-20 2006-02-23 Medtronic Inc. Drug eluting medical device
US20060051390A1 (en) * 2004-09-03 2006-03-09 Schwarz Marlene C Medical devices having self-forming rate-controlling barrier for drug release
EP2452670A1 (de) * 2004-10-01 2012-05-16 Ramscor, Inc. Einfach implantierbare Arzneimittelzusammensetzungen mit verzögerter Freisetzung
BRPI0516972A (pt) 2004-10-26 2008-09-30 Angeletti P Ist Ricerche Bio composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
WO2007001624A2 (en) * 2005-06-28 2007-01-04 Microchips, Inc. Medical and dental implant devices for controlled drug delivery
US8722074B2 (en) * 2005-07-19 2014-05-13 Boston Scientific Scimed, Inc. Medical devices containing radiation resistant polymers
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
US20070053952A1 (en) * 2005-09-07 2007-03-08 Medtronic Vascular, Inc. Nitric oxide-releasing polymers derived from modified polymers
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
WO2007038246A2 (en) * 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US8784860B2 (en) * 2005-10-27 2014-07-22 Cordis Corporation Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101505723A (zh) * 2006-06-22 2009-08-12 南佛罗里达大学 胶原支架、具有其的医用植入物以及使用方法
CA2656191C (en) * 2006-06-28 2015-12-08 Surmodics, Inc. Hydrophilic active agent eluting polymeric matrices with microparticles
US7731987B2 (en) * 2006-07-13 2010-06-08 Advanced Cardiovascular Systems, Inc. Implantable medical device comprising a pro-healing poly(ester-amide)
US8506984B2 (en) * 2006-07-26 2013-08-13 Cordis Corporation Therapeutic agent elution control process
US20080057103A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of using medical devices for controlled drug release
WO2008039749A2 (en) * 2006-09-25 2008-04-03 Surmodics, Inc. Multi-layered coatings and methods for controlling elution of active agents
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) * 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders

Also Published As

Publication number Publication date
US8124601B2 (en) 2012-02-28
ES2362560T3 (es) 2011-07-07
JP2011504178A (ja) 2011-02-03
ATE505473T1 (de) 2011-04-15
EP2215095B1 (de) 2011-04-13
US20090130056A1 (en) 2009-05-21
CN101918412A (zh) 2010-12-15
CN101918412B (zh) 2013-06-05
EP2215095A1 (de) 2010-08-11
WO2009067392A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
DK1987038T3 (da) HCV NS5B-hæmmere
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA200900298A1 (ru) Ингибиторы вируса гепатита с
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
EA201001273A1 (ru) Ингибиторы вируса гепатита с
EA201101082A1 (ru) Ингибиторы вируса гепатита с
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
EA201100390A1 (ru) Соединения для лечения гепатита с
DK2250163T3 (da) Hepatitis C-virusinhibitorer
EA200900297A1 (ru) Ингибиторы вируса гепатита с
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA200870164A1 (ru) Лечение вирусного гепатита
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
ATE531373T1 (de) Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren